PTC Therapeutics outlines 19%-36% 2026 product revenue growth target as Sephience momentum accelerates globally
Source: SeekingAlpha
2026-02-20 13:25:46 ET
More on PTC Therapeutics
- PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
- PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- PTC Therapeutics GAAP EPS of -$1.67 misses by $1.70, revenue of $164.6M misses by $124.65M
- PTC Therapeutics Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
PTC Therapeutics outlines 19%-36% 2026 product revenue growth target as Sephience momentum accelerates globally
PTC Therapeutics Inc.
NASDAQ: PTCT
PTCT Trading
8.25% G/L:
$66.815 Last:
1,048,328 Volume:
$63.19 Open:
PTCT Latest News
March 03, 2026 10:11:53 am
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
February 19, 2026 04:01:00 pm
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PTCT Stock Data
$5,800,830,036
75,872,448
1.06%
134
N/A
Biotechnology & Life Sciences
Healthcare
US
Warren
